Both in Canada and the US, the most critical problem to be addressed for commercial exploitation of C. sativa is the possible unauthorized drug use of the plant. Indeed, the reason hemp cultivation was made illegal in North America was concern that the hemp crop was a drug menace. The drug potential is, for practical purposes, measured by the presence of THC. THC is the world’s most popular illicit chemical, and indeed the fourth most popular recreational drug, after caffeine, alcohol, and nicotine. “Industrial hemp” is a phrase that has become common to designate hemp used for commercial non-intoxicant purposes. Small and Cronquist (1976) split C. sativa into two subspecies: C. sativa subsp. sativa, with less than 0.3% (dry weight) of THC in the upper (reproductive) part of the plant, and C. sativa subsp. indica (Lam.) E. Small & Cronq. with more than 0.3% THC. This classification has since been adopted in the European Community, Canada, and parts of Australia as a dividing line between cultivars that can be legally cultivated under license and forms that are considered to have too high a drug potential. For a period, 0.3% was also the allowable THC content limit for cultivation of hemp in the Soviet Union. In the US, Drug Enforcement Agency guidelines issued Dec. 7, 1999 expressly allowed products with a THC content of less than 0.3% to enter the US without a license; but subsequently permissible levels have been a source of continuing contention. Marijuana in the illicit market typically has a THC content of 5% to 10% (levels as high as 25% have been reported), and as a point of interest, a current Canadian government experimental medicinal marijuana production contract calls for the production of 6% marijuana. As noted above, a level of about 1% THC is considered the threshold for marijuana to have intoxicating potential, so the 0.3% level is conservative, and some countries (e.g. parts of Australia, Switzerland) have permitted the cultivation of cultivars with higher levels. It should be appreciated that there is considerable variation in THC content in different parts of the plant. THC content increases in the following order: achenes (excluding bracts), roots, large stems, smaller stems, older and larger leaves, younger and smaller leaves, flowers, perigonal bracts covering both the female flowers and fruits. It is well known in the illicit trade how to screen off the more potent fractions of the plant in order to increase THC levels in resultant drug products. Nevertheless, a level of 0.3% THC in the flowering parts of the plant is reflective of material that is too low in intoxicant potential to actually be used practically for illicit production of marijuana or other types of cannabis drugs. Below, the problem of permissible levels of THC in food products made from hempseed is discussed.
I can’t disagree more with attacking “Big Pharma” or Trump with regards to fixing this problem! Screw the political affiliations for now, let’s change the whole Schedule 1 nightmare. We’re steeped in technology and we have insanely archaic drug laws. Worse, our gov then pressures the countries we give money to (which is all of them) to follow suit by adopting our effed up way. Schedule 1 needs to be dismantled. The research can’t be done on anything listed with very few exceptions. There’s other Sched.1 drugs that need to be available for research by legitimate people, there’s lots of exciting research in psychedelics that’s stalled by archaic laws. That part might just require big pharma to help.
Three controlled trials demonstrated that oral THC has variable effects on appetite stimulation and weight loss in patients with advanced malignancies and human immunodeficiency virus (HIV) infection. One study evaluated the efficacy of dronabinol alone or with megestrol acetate compared with that of megestrol acetate alone for managing cancer-associated anorexia. In this randomized, double-blind study of 469 adults with advanced cancer and weight loss, patients received 2.5 mg of oral THC twice daily, 800 mg of oral megestrol daily, or both. Appetite increased by 75% in the megestrol group and weight increased by 11%, compared with a 49% increase in appetite and a 3% increase in weight in the oral THC group after 8 to 11 weeks of treatment. These two differences were statistically significant. Furthermore, the combined therapy did not offer additional benefits beyond those provided by megestrol acetate alone. The authors concluded that dronabinol did little to promote appetite or weight gain in advanced cancer patients compared with megestrol acetate. However, a smaller, placebo-controlled trial of dronabinol in cancer patients demonstrated improved and enhanced chemosensory perception in the cannabinoid group—food tasted better, appetite increased, and the proportion of calories consumed as protein was greater than in the placebo recipients.
At least 38 states considered legislation related to industrial hemp in 2018. These bills ranged from clarifying existing laws to establishing new licensing requirements and programs. At least 5 states – Alaska, Arizona, Kansas, Missouri and Oklahoma – enacted legislation in 2018 establishing hemp research and industrial hemp pilot programs. Georgia adopted a resolution to create the House Study Committee on Industrial Hemp Production. States, already allowing for industrial hemp programs, continued to consider policies related to licensure, funding, seed certification, and other issues. For example, Tennessee amended its Commercial Feed Law to include hemp.
For example, the six hemp oil companies the FDA had investigated in February had explicitly advertised CBD products for use in the “cure, mitigation, treatment, or prevention of diseases.” The agency sent warning letters to the companies, ordering them to change their product labeling or face potential legal action. Then, in May, the FDA announced it was excluding products containing cannabidiol from its definition of dietary supplements altogether. Hard, the spokesman for Medical Marijuana, Inc., said the company views “these developments as positive because this allows the debate regarding CBD to come to the forefront.” He characterized the FDA’s May announcement as “an opinion” and added, “Medical Marijuana, Inc. and HempMeds, along with industry associations, are working on determining how we can come to a mutual understanding on the matter with the FDA.”
One of the biggest players in this new industry is Medical Marijuana, Inc., a company formed in 2009 that operates out of Poway, California, just north of San Diego. It has played a leading role in the so-called Green Rush, as businesses have moved quickly to capitalize on the gradual legalization of marijuana for medical and recreational purposes by states across the country. The company’s spokesman, Andrew Hard, boasted that Medical Marijuana, Inc., “created the CBD industry and was first to market with CBD products.” Through its various subsidiaries, Medical Marijuana, Inc. sells some of the most recognizable products on the cannabis market— everything from Cibaderm CBD-infused shampoo to CanChew chewing gum. In 2014, the company generated $14.5 million in revenue.
In the United States, over three million people suffer from epilepsy – 470,000 of those people are children. Epilepsy is a disorder of the brain that causes seizures – of which there are over thirty different kinds, ranging from mild and infrequent to life-threatening. Not surprisingly, people with epilepsy face significant challenges – from the cost of healthcare to work limitations and social isolation.
“Specialty pulp” is the most important component of the hemp industry of the EU, and is expected to remain its core market for the foreseeable future. The most important specialty pulp products made from hemp are cigarette paper (Fig. 16), bank notes, technical filters, and hygiene products. Other uses include art papers and tea bags. Several of these applications take advantage of hemp’s high tear and wet strength. This is considered to be a highly stable, high-priced niche market in Europe, where hemp has an 87% market share of the “specialty pulp” sector (Karus et al. 2000). In Europe, decortication/refining machines are available that can produce 10 t/hour of hemp fiber suitable for such pulp use. North American capacity for hemp pulp production and value-added processing is much more limited than that of Europe, and this industry is negligible in North America.
Cannabis, also referred to as marijuana, has been an integral part of human civilizations for millennia. Both as a medicine and as a recreational substance, cannabis is the most popular illicit drug in the world. Today, the legal landscape that has prohibited marijuana for much of the twentieth century is giving way to decriminalization and full legalization. Legal, commercial cannabis businesses are already making an enormous economic impact.
No, as long as the plant is used correctly then no it’s not a bad thing. I’m sure there’s probably more good capability about that plant that people know or don’t know. No matter how it’s administered, as long as used properly it’s a good thing. It probably has more healing capabilities than people know about and since big Pharma or whoever it is out there discovered this, that’s probably why they made it illegal for all we know. Yes, I know there’s no money in cure which would hurt big Pharma but oh well! If they want to keep us away from the cure and keep us all sick, I say go for it anyway and go for the cure.
My mom is late stage dementia. We have tried coconut oil/black pepper/curcumin combo for years. Gives only tine bit of help, and is not something that reverses dementia. Maybe in someone who can score better than a 14 on the mme it could be of help. But cannabinoid is a different story. Cannabinoids produce better results in less time. Can't say yet that they will reverse anything though.
THC, an intoxicating and illegal substance, is responsible for causing marijuana users to get “high.” Unlike THC, CBD is non-psychoactive because it does not act on the same pathways as THC. Thus, it is impossible to get “high” by smoking or ingesting CBD or CBD oil extracted from industrial hemp plants, as they only have minuscule traces of THC (<0.3%).
In the United States, the CBD drug Epidiolex has been approved by the Food and Drug Administration for treatment of two epilepsy disorders. The U.S. Drug Enforcement Administration has assigned Epidiolex a Schedule V classification while non-Epidiolex CBD remains a Schedule I drug prohibited for any use. CBD is not scheduled under any United Nations drug control treaties, and in 2018 the World Health Organization recommended that it remain unscheduled.
A wide variety of hemp clothing, footwear, and food products are now available in North America. Some American manufacturers and distributors have chosen to exploit the association of hemp products with marijuana in their advertising. Such marketing is unfortunate, sending the message that some in the industry are indifferent to the negative image that this generates in the minds of much of the potential consuming public. Admittedly, such advertising works. But marketing based on the healthful and tasteful properties of hemp food products, the durable nature of hemp textiles, and the environmental advantages of the crop has proven to be widely acceptable, and is likely to promote the long term development of hemp industries.
Low concentrations of CBD aren’t the only concern, either. Cannabis plants are hardy and tough, and their thick stalks possess a special property: bioremediation. When grown in contaminated soil, hemp plants absorb heavy metals and other chemical waste, effectively cleansing the terrain. While all plants absorb some chemicals from the soil, the structure, size, and genetic makeup of hemp make it especially adept at this task. Cannabis is so effective that crops of industrial hemp were planted in the aftermath of the 1986 Chernobyl disaster to help purify heavily irradiated soil. When hemp stalks are used for fiber, paper, and other nonconsumptive industrial purposes, the contaminants absorbed into the plants pose no threat to humans.
Cannabis (also called pot, marijuana, weed, dope, grass, mull, dak, hash, smoke, buds, skunk, cabbage, ganja, reefer) is the most commonly used illegal drug in New Zealand. Cannabis comes from the Cannabis Sativa plant and is used both for recreational and medicinal purposes. As a recreational drug, it can be used in a dried plant, resin, or oil form. The potency of cannabis depends on it's concentration of THC, which is higher in resin and oil than in the dried plant. The psychoactive potency of cannabis depends on its concentration of THC, which is higher in resin and hash oil. Cannabis is widely available in New Zealand.
Textile expert Elizabeth Wayland Barber summarizes the historical evidence that Cannabis sativa, "grew and was known in the Neolithic period all across the northern latitudes, from Europe (Germany, Switzerland, Austria, Romania, Ukraine) to East Asia (Tibet and China)," but, "textile use of Cannabis sativa does not surface for certain in the West until relatively late, namely the Iron Age." "I strongly suspect, however, that what catapulted hemp to sudden fame and fortune as a cultigen and caused it to spread rapidly westwards in the first millennium B.C. was the spread of the habit of pot-smoking from somewhere in south-central Asia, where the drug-bearing variety of the plant originally occurred. The linguistic evidence strongly supports this theory, both as to time and direction of spread and as to cause."
From the 1950s to the 1980s, the Soviet Union was the world's largest producer of hemp (3,000 km2 in 1970). The main production areas were in Ukraine, the Kursk and Orel regions of Russia, and near the Polish border. Since its inception in 1931, the Hemp Breeding Department at the Institute of Bast Crops in Hlukhiv (Glukhov), Ukraine, has been one of the world's largest centers for developing new hemp varieties, focusing on improving fiber quality, per-hectare yields, and low THC content.
In the United States, the legality of medical marijuana varies in substantial ways from state to state. There are currently 29 US states with legal medical cannabis laws, as well as the District of Columbia. That leaves 21 states where medical marijuana is entirely prohibited. Marijuana cultivation, possession, and use in any form is illegal at the federal level.
The world-leading producer of hemp is China, which produces more than 70% of the world output. France ranks second with about a quarter of the world production. Smaller production occurs in the rest of Europe, Chile, and North Korea. Over 30 countries produce industrial hemp, including Australia, Austria, Canada, Chile, China, Denmark, Egypt, Finland, Great Britain, Germany, Greece, Hungary, India, Italy, Japan, Korea, Netherlands, New Zealand, Poland, Portugal, Romania, Russia, Slovenia, Spain, Sweden, Switzerland, Thailand, Turkey and Ukraine.
As the range of Tweed and CraftGrow brands and products will change in the Shop over time, we recommend the Spectrum Cannabis brand when consistent access to the same product is important to you and your condition. If you have been taking a Tweed product that is no longer carried or available in our store, we have created a comprehensive table for you to explore alternative options. The goal of this table is to support treatment decisions with products most similar to what you have been taking, when a change is necessary. Learn More
On Oct. 22 and 23, KDA participated in four informational meetings about Industrial Hemp in Manhattan, Salina, Colby and Garden City hosted by Kansas Farmers Union. The presentation shared by KDA at those meetings can be seen here: KDA Industrial Hemp Presentation. Information on the event, including the video of the guest presenter, can be found on the Kansas Farmers Union website.
Senate Majority Leader Mitch McConnell (R-KY) introduced new legislation in April that would declassify non-psychoactive cannabis varieties -- more commonly referred to as hemp -- from the Controlled Substances Act. The legislative proposal comes as part of McConnell's Hemp Farming Act of 2018, which would remove barriers placed on banking access and water rights in addition to legalizing the crop.
Jump up ^ Parliament of the Czech Republic (1998), Explanatory Report to Act No. 112/1998 Coll., which amends the Act No. 140/1961 Coll., the Criminal Code, and the Act No. 200/1990 Coll., on misdemeanors (in Czech), Prague "Podle čl. 36 Jednotné úmluvy o omamných látkách ze dne 31. března 1961 (č. 47/1965 Sb.) se signatáři zavazují k trestnímu postihu tam uvedených forem nakládání s drogami včetně jejich držby. Návrh upouští od dosavadní beztrestnosti držby omamných a psychotropních látek a jedů pro svoji potřebu. Dosavadní beztrestnost totiž eliminuje v řadě případů možnost postihu dealerů a distributorů drog."
Several studies have demonstrated the therapeutic effects of cannabinoids for nausea and vomiting in the advanced stages of illnesses such as cancer and AIDS. Dronabinol (tetrahydrocannabinol) has been available by prescription for more than a decade in the USA. Other therapeutic uses of cannabinoids are being demonstrated by controlled studies, including treatment of asthma and glaucoma, as an antidepressant, appetite stimulant, anticonvulsant and anti-spasmodic, research in this area should continue. For example, more basic research on the central and peripheral mechanisms of the effects of cannabinoids on gastrointestinal function may improve the ability to alleviate nausea and emesis. More research is needed on the basic neuropharmacology of THC and other cannabinoids so that better therapeutic agents can be found.
Cannabis sativa L. subsp. sativa var. sativa is the variety grown for industrial use, while C. sativa subsp. indica generally has poor fiber quality and female buds from this variety are primarily used for recreational and medicinal purposes. The major differences between the two types of plants are the appearance, and the amount of Δ9-tetrahydrocannabinol (THC) secreted in a resinous mixture by epidermal hairs called glandular trichomes, although they can also be distinguished genetically. Oilseed and fiber varieties of Cannabis approved for industrial hemp production produce only minute amounts of this psychoactive drug, not enough for any physical or psychological effects. Typically, hemp contains below 0.3% THC, while cultivars of Cannabis grown for medicinal or recreational use can contain anywhere from 2% to over 20%.
Nabiximols (Sativex), a Cannabis extract with a 1:1 ratio of THC:CBD, is approved in Canada (under the Notice of Compliance with Conditions) for symptomatic relief of pain in advanced cancer and multiple sclerosis. Canada, New Zealand, and some countries in Europe also approve nabiximols for spasticity of multiple sclerosis, a common symptom that may include muscle stiffness, reduced mobility, and pain, and for which existing therapy is unsatisfactory.
Put simply, “indica” strains are those associated with a strong body-high, feelings of sedation and relaxation. For this reason, indicas are often thought of as the “heavier” strains of cannabis, offering stronger highs that impact the whole body. They’re popular among marijuana users as pain relieving and sleep-inducing strains. Indicas are especially popular among medical cannabis patients.
The first example of the use of hempcrete was in 1986 in France with the renovation of the Maison de la Turquie in Nogent-sur-Seine by the innovator Charles Rasetti. In the UK hemp lime was first used in 2000 for the construction of two test dwellings in Haverhill. Designed by Modece Architects, who pioneered hemp's use in UK construction, the hemp houses were monitored in comparison with other standard dwellings by BRE. Completed in 2009, the Renewable House is one of the most technologically advanced made from hemp-based materials. The first US home made of hemp-based materials was completed in August 2010 in Asheville, North Carolina.